Pembrolizumab plus axitinib for metastatic papillary and chromophobe kidney cancer
Non-clear cell kidney cancer is a group of different subtypes [...]
Real-world survival outcomes of metastatic papillary and clear cell kidney cancer
In this study, real world data is used to compare [...]
Long-term data support first-line use of avelumab and axitinib for advanced kidney cancer
A recent paper published in The Oncologist has shown that [...]
Does neoadjuvant therapy improve outcomes in localised kidney cancer?
At the 2023 Society of Urologic Oncology (SUO) Annual Meeting, [...]
Shared decision-making in kidney cancer
Over 400,000 people are diagnosed with kidney cancer globally each [...]
New method enables early detection of cancer
When cancer is diagnosed early, it is easier to treat [...]
Psychological distress in patients treated for kidney cancer
This review of the literature looked at how common psychological [...]
BMI and outcomes in patients with metastatic kidney cancer treated with first-line TKIs
This study looked at whether high or low body mass [...]
NICE approves pembrolizumab plus lenvatinib combination for advanced kidney cancer
The National Institute for Health and Care Excellence (NICE) has [...]
5-year outcomes after SABR for primary kidney cancer
Stereotactic ablative body radiotherapy (SABR) uses an intense beam of [...]
